Enjoy this round-up featuring breaking news about stem cells, cell and gene therapies, exosomes, cord blood, and beyond. [Read more…]
5 Strategies To Stay on Top of a Changing Cell Therapy Industry
Author: Jonathan Wofford, General Manager of WellSky’s Biotherapies Division
As operations for cell and gene therapy programs become more demanding and supply chain management becomes more complex, your program may face various challenges adapting to these changes. For example, increasing manufacturing and procedure volumes in combination with new and changing protocols will require the use of more automated, flexible and efficient processes. Tightening regulations will require greater documentation and process control. As cell and gene therapies continue to grow in clinical application, payers, study sponsors, and other agencies will require more data and reporting. [Read more…]
RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium
RoosterGEM™, a complete genetic engineering medium, empowers product developers to realize up to four-fold increased transduction efficiency in primary cells, and achieve a greater than 50% reduction in overall gene transfer cost.
Frederick, MD, May 20, 2021 – RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. [Read more…]
Organicell Receives Approval In Pakistan For The Use Of Zofin™ For Compassionate Grounds For COVID-19
Clinical Trials To Commence Immediately
Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]
Axion BioSystems’ Bioelectronic Assays Aid in the Development of Cancer Immunotherapies
The immunotherapy field is booming, with cell therapies like chimeric antigen receptor (CAR) T cells taking the lead. According to one forecast, the market is expected to reach $6.1 billion in size by 2030 for CAR-T therapies alone. The FDA approved the world’s first CAR-T therapy, Kymriah, in 2017, and it is now available at over 130 treatment centers across the United States. [Read more…]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 47
- Next Page »